SENATE 1523117th CongressRead twice and referred to the Committee on Health, Education, Labor, and Pensions.
Drug Price Transparency Act of 2021
- Last Action
- 4/29/2021
Actions
- 2021-04-29Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2021-04-29Introduced in Senate
CRS Summary
As of 2021-04-29 (00)
Drug Price Transparency Act of 2021
This bill provides statutory authority for the limitation on which type of prescription drug rebates are exempt from federal anti-kickback laws.
Specifically, a rebate from a drug manufacturer to a health insurer or pharmacy benefit manager is exempt only if the rebate (1) is disclosed to the consumer at the point of sale, or (2) is a flat fee paid for pharmacy benefit management services.
Cosponsors (2)
- Cindy Hyde-Smith (R-MS)
- Roger Marshall (R-KS)
Subjects
- Employee benefits and pensions
- Health care costs and insurance
- Inflation and prices
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.